采用西达本胺联合自体造血干细胞移植治疗难治性弥漫大 B 细胞淋巴瘤 1 例报告

Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.

机构信息

Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University, Chengdu.

Department of Hematology, The affiliated hospital of Southwest Medical University, Luzhou, Sichuan, China.

出版信息

Anticancer Drugs. 2021 Sep 1;32(8):886-889. doi: 10.1097/CAD.0000000000001093.

DOI:10.1097/CAD.0000000000001093

PMID:34145178

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, with certain DLBCLs affecting specific anatomic sites, such as primary cutaneous DLBCL, leg type and intravascular large B-cell lymphoma. However, the occurrence of secondary cutaneous involvement in DLBCL while patients are undergoing regular chemotherapy is rare. In this study, we reported a case of refractory diffuse large B-cell lymphoma with cutaneous involvement that achieved complete remission for more than 4 years with epigenetic regulation of chidamide in combination with chemotherapy and autologous hematopoietic stem cell transplantation including a pretreatment regimen containing chidamide.

摘要

弥漫性大 B 细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤中最常见的亚型，某些 DLBCL 影响特定的解剖部位，如原发性皮肤 DLBCL、腿型和血管内大 B 细胞淋巴瘤。然而，在接受常规化疗的 DLBCL 患者中，继发性皮肤受累的发生较为罕见。在本研究中，我们报告了一例难治性弥漫性大 B 细胞淋巴瘤伴皮肤受累患者，在接受包含西达本胺的预处理方案的化疗和自体造血干细胞移植联合西达本胺的表观遗传调控治疗后，获得了超过 4 年的完全缓解。